IFNA1 and COVID-19: Previously investigated emergency treatment regimens for critically ill COVID-19 patients with anti-IFN-I autoAbs have included plasmapheresis to transiently remove pathogenic autoAbs from circulating blood, as well as treatment of patients harboring anti-IFNα autoAbs with IFNβ to bypass neutralizing autoAbs and thereby restore IFN-I function (Bastard et al., 2021b; de Prost et al., 2021).